Corganics is a Dallas-based life sciences company that makes scientifically formulated, physician-advised clinical CBD therapies sold exclusively through licensed healthcare professionals. Its broad-spectrum, THC-free products use Advanced Lipid Technology (A.L.T.) to improve bioavailability and are manufactured in cGMP-compliant, NSF-certified facilities with third-party testing and IRB-approved data. Founded in 2020 by pharmaceutical executives Chad Collins and Reggie Gatewood, the company aims to make CBD a trusted, clinic-grade therapy rather than a retail gamble.
Chad Collins is the co-founder, chairman and CEO of Corganics, a Dallas-based clinical cannabinoid company that sells pharmaceutical-grade, broad-spectrum CBD exclusively through healthcare professionals. A 20-year veteran of biopharma, payor systems and medical devices - including stints as a VP at Galderma and CEO of Boston Select Asset Group - he co-founded Corganics in January 2020 with Reggie Gatewood to drag CBD out of what he calls the retail 'Wild West' and into the clinic. He is also the author of 'Run to the Fire,' the true story of his father, a doubly amputated Vietnam veteran, with a foreword by NFL Hall of Famer Roger Staubach.